Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): KT-474

            Therapeutic Area: Dermatology Product Name: KT-474

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 12, 2020

            Details:

            Kymera Therapeutics will present poster titled "Targeted Protein Degradation Beyond Oncology,” and share recent data related to the company’s IRAK4 program including findings from the company’s non-interventional trial in hidradenitis suppurativa (HS) patients.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): KT-474

            Therapeutic Area: Dermatology Product Name: KT-474

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 09, 2020

            Details:

            Results support clinical development of IRAK4-targeted protein degrader in hidradenitis suppurativa (HS) and other IL-1R/TLR-driven autoimmune and inflammatory diseases, with Phase 1 trial on track for start in 2021.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): KT-474

            Therapeutic Area: Dermatology Product Name: KT-474

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Morgan Stanley

            Deal Size: $100.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering July 31, 2020

            Details:

            Kymera expects to file an IND for KT-474, an orally bioavailable IRAK4 degrader, in the 1H 2021. If approved, the company will initiate a Phase 1 trial in adult healthy volunteers and hidradenitis suppurativa (HS) and atopic dermatitis (AD) patients.